Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.03 AUD
Change Today -0.003 / -8.33%
Volume 1.5M
As of 1:57 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

phosphagenics ltd (POH) Snapshot

Open
A$0.04
Previous Close
A$0.04
Day High
A$0.04
Day Low
A$0.03
52 Week High
08/7/14 - A$0.11
52 Week Low
04/16/15 - A$0.03
Market Cap
41.6M
Average Volume 10 Days
4.3M
EPS TTM
A$-0.0067
Shares Outstanding
1.3B
EX-Date
08/22/97
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHOSPHAGENICS LTD (POH)

Related News

No related news articles were found.

phosphagenics ltd (POH) Related Businessweek News

No Related Businessweek News Found

phosphagenics ltd (POH) Details

Phosphagenics Limited, a biotechnology company, produces, sells, and licenses products for the pharmaceutical, cosmetics, and animal health industries. It is involved in the commercialization of drug delivery applications based on its transdermal Targeted Penetration Matrix (TPM) technology that is used to deliver pharmaceutical and nutraceutical products. Its Skin Care segment provides a range of products to enhance the appearance of skin. The company’s Pain Portfolio segment focuses on enhancing the delivery of opioids used for pain treatment through the skin. Phosphagenics Limited serves various customers in Australia, Germany, Switzerland, and the United States. The company was formerly known as Vital Capital Limited and changed its name to Phosphagenics Limited in 2004. Phosphagenics Limited is headquartered in Clayton, Australia.

41 Employees
Last Reported Date: 02/26/15

phosphagenics ltd (POH) Top Compensated Officers

Founder, President and Executive Director
Total Annual Compensation: A$285.2K
Chief Financial Officer
Total Annual Compensation: A$166.2K
General Counsel
Total Annual Compensation: A$244.7K
Vice President of Business Development & Comm...
Total Annual Compensation: A$229.6K
General Manager of Personal Care
Total Annual Compensation: A$151.0K
Compensation as of Fiscal Year 2014.

phosphagenics ltd (POH) Key Developments

Phosphagenics Limited Announces Board Appointments

Phosphagenics Limited announced that it has appointed three new directors to the board. The new directors include Dr. Greg Collier, Mr. Peter Lankau and Dr. Ross Murdoch. Dr. Greg Collier is currently the CEO of and has more than 20 years' experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialization. He has executed multiple commercial transactions and has successfully taken a drug from discovery through to regulatory approval. Mr. Peter Lankau served as CEO of Endo Pharmaceuticals Inc. from 2005 to 2008 and as Chief Operating Officer from 2003 to 2005. In recent years Mr. Lankau has served on multiple company boards including Nautilus Neuroscience Inc. Dr. Ross Murdoch has over 25 years' experience in the global Healthcare, Pharmaceutical and Biotech industries and has held senior and executive positions with global Pharmaceutical companies such as GlaxoSmithKline, Astra Zeneca and Shire Pharmaceuticals where he built significant specialized business divisions.

Phosphagenics Limited(ASX:POH) dropped from S&P/ASX All Ordinaries Index

Phosphagenics Limited(ASX:POH) dropped from S&P/ASX All Ordinaries Index

Phosphagenics Limited Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2014

Phosphagenics Limited announced audited consolidated earnings results for the year ended December 31, 2014. For the year, the company reported total revenue of AUD 2,505,000 against AUD 1,357,000 a year ago. The overwhelming contributor was the sales of Vital ET by the company's partner Ashland, which amounted to approximately AUD 1.5 million (compared to less than AUD 0.3 million in 2013). Loss before income tax was AUD 7,434,000 against AUD 10,671,000 a year ago. Loss for period was AUD 8,935,000 against AUD 12,607,000 a year ago. Basic and diluted per share for loss attributable to the ordinary equity holders of the company were 0.80 cents against 1.24 cents a year ago. Net cash used in operating activities was AUD 6,739,000 against AUD 8,578,000 a year ago. Purchase of plant and equipment was AUD 95,000 against AUD 133,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
POH:AU A$0.03 AUD -0.003

POH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Durect Corp $2.11 USD -0.46
View Industry Companies
 

Industry Analysis

POH

Industry Average

Valuation POH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHOSPHAGENICS LTD, please visit www.phosphagenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.